An antibody-like peptidic network for anti-angiogenesis

Kuo Zhang¹, Hui Zhang², Xiao-Ran Zou¹, Ying Hu³, Da-Yong Hou⁴, Jia-Qi Fan⁴, Chao Yang⁴, Zi-Ming Chen⁴, Shi-Fang Wen⁴, Hui Cao⁵, Pei-Pei Yang⁴, Lei Wang⁶

Affiliations

¹ CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China; Department of Materials Physics and Chemistry, School of Materials Science and Engineering, University of Science and Technology Beijing, No. 30 Xueyuan Road, Beijing, 100083, China.
² Shanghai Jiao Tong University School of Medicine, 227 Chongqing South Road, Shanghai, 200025, China.
³ Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600, Yishan Road, Shanghai, 200233, China. Electronic address: 13046@6hospital.com.
⁴ CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China.
⁵ Department of Materials Physics and Chemistry, School of Materials Science and Engineering, University of Science and Technology Beijing, No. 30 Xueyuan Road, Beijing, 100083, China. Electronic address: caohui@mater.ustb.edu.cn.
⁶ CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China. Electronic address: wanglei@nanoctr.cn.

PMID: 34051670
DOI: 10.1016/j.biomaterials.2021.120900

An antibody-like peptidic network for anti-angiogenesis

Kuo Zhang et al. Biomaterials. 2021 Aug.

. 2021 Aug:275:120900.

doi: 10.1016/j.biomaterials.2021.120900. Epub 2021 May 18.

Authors

Kuo Zhang¹, Hui Zhang², Xiao-Ran Zou¹, Ying Hu³, Da-Yong Hou⁴, Jia-Qi Fan⁴, Chao Yang⁴, Zi-Ming Chen⁴, Shi-Fang Wen⁴, Hui Cao⁵, Pei-Pei Yang⁴, Lei Wang⁶

Affiliations

¹ CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China; Department of Materials Physics and Chemistry, School of Materials Science and Engineering, University of Science and Technology Beijing, No. 30 Xueyuan Road, Beijing, 100083, China.
² Shanghai Jiao Tong University School of Medicine, 227 Chongqing South Road, Shanghai, 200025, China.
³ Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600, Yishan Road, Shanghai, 200233, China. Electronic address: 13046@6hospital.com.
⁴ CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China.
⁵ Department of Materials Physics and Chemistry, School of Materials Science and Engineering, University of Science and Technology Beijing, No. 30 Xueyuan Road, Beijing, 100083, China. Electronic address: caohui@mater.ustb.edu.cn.
⁶ CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China. Electronic address: wanglei@nanoctr.cn.

PMID: 34051670
DOI: 10.1016/j.biomaterials.2021.120900

Abstract

Different from chemical (small molecular inhibitor) and biological (monoclonal antibody) drugs, herein, based on angiogenesis-related neuropilin-1 (NRP-1), we develop a biomimetic superstructure drug, i.e. an antibody-like peptidic network (ALPN) to achieve the high-efficient treatment of choroidal neovascularization (CNV). The ALPN in nanoparticulated formulation (ALPN-NP_S) can bind NRP-1 through targeting unit and form fibrous peptidic networks trapping NRP-1 on the surface of endothelial cells (ECs), leading to anti-angiogenesis. The ALPN shows high-efficacy against angiogenesis in CNV rat model ascribed to the superstructure-enhanced binding and blockage of NRP-1. The very low dose of ALPN (0.263 μg/Kg) exhibits similar anti-angiogenesis effect comparing with monoclonal antibody bevacizumab (23.5 μg/Kg), which shows potential advantages over traditional monoclonal antibodies.

Keywords: Angiogenesis; Antibody; Biomimetic; Peptide; Self-assembly.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

An antibody-like peptidic network for anti-angiogenesis

Affiliations

An antibody-like peptidic network for anti-angiogenesis

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous